Drug intelligence / Profile preview

VX-006

Development stage: Phase 1
Lead developer: Vaxon Biotech
Modality: Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

VX-006 is a therapeutic cancer vaccine developed by VAXON Biotech. It targets three tumor-associated antigens: HER2 (receptor tyrosine-protein kinase erbB-2), MAGEA1 (melanoma-associated antigen 1), and TERT (telomerase reverse transcriptase). The mechanism of action involves antagonism or inhibition of these targets, aiming to stimulate an immune response against tumors expressing these antigens. The vaccine has been investigated primarily for the treatment of neoplasms, with clinical trials conducted in patients with solid tumors who are HLA-A*02 positive[1].

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)TERT (Telomerase)MAGEA1 (Melanoma-associated antigen 1)

Beyond the preview

Go deeper on VX-006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VX-006.

Explore the full profile